UP

Novavax COVID-19 vaccine more than 90% effective in U.S. trial

Home page World
12 Punto 14 Punto 16 Punto 18 Punto
Novavax COVID-19 vaccine more than 90% effective in U.S. trial

Novavax Inc on Monday said its COVID-19 vaccine was more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based clinical trial.

Axar.az reports that the study of nearly 30,000 volunteers in the United States and Mexico puts Novavax on track to file for emergency authorization in the United States and elsewhere in the third quarter of 2021, the company said.

The protein-based vaccine was more than 93% effective against the more easily transmissible predominant coronavirus variants that have caused concern among scientists and public health officials, Novavax said.

Protein-based vaccines are a conventional approach that use purified pieces of the virus to spur an immune response, such as those used against whooping cough and shingles.

Date
2021.06.14 / 23:32
Author
Axar.az
See also

Peskov says Putin-Trump meeting will be brief

Imamoglu sentenced to 2 years and 1 month in CHP case

British Airways plane veers off taxiway at Heathrow Airport

German foreign minister meets Pashinyan in Yerevan

Pashinyan calls for cooperation on shared rivers

Lammy urges Burnham to pledge UK return to EU

Putin takes nuclear briefcase on visit to China - Video

EES problems leave British travellers stranded in Europe

Ukrainian military losses updated on 1,729th day of war

Pashinyan announces practical phase of TRIPP project

Latest
Xocalı soyqırımı — 1992-ci il Bağla
Bize yazin Bağla
ArxivBağla